CD33 and acute myeloid leukemia: They achieved around 30%–60% of transduction rates, and CD33 CAR-NK efficiently eliminated OCI-AML2 and primary AML cells in vitro, even at low effector:target ratios, and they were able to kill tumor cells in rechallenge experiments after 3 rounds of repeated antigen stimulation (Albinger et al., 2022).